Recombinant DENV3 VLP (399-492aa)

• Cat.No.: VLP-08D
• Product Overview: Recombinant Dengue Virus serotype 3 virus-like particle recombinant antigen consisting of Envelope, pre-Membrane and Membrane protein produced in 293 human cells. The Cterminal 20% of the dengue Envelope protein was replaced by the corresponding Japanese encephalitis virus SA-14 sequence (Envelope protein amino acids 399-492). The replaced sequence corresponds to the transmembrane and intraparticle portion of the protein.

Specification

• Species: DENV3
• Source: HEK293
• ProteinLength: 399-492
• Description: Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.
• Form: Liquid
• Purity: >95% by SDS-PAGE
• Stability: At +4 centigrade: 1 week.
  At -80 centigrade: 1 year.
  Freezing: Can be frozen, but avoid multiple freeze-thaw cycles.
• Storage: Short Term Storage: +4 centigrade
  Long Term Storage: -80 centigrade
• Storage Buffer: 10mM sodium phosphate, 20mM sodium citrate, 154mM sodium chloride, pH7.4.
• Shipping: Dry ice.

Gene Information

• Official Symbol: VLP
• Synonyms: VLP; Virus-Like Particles; VLPs